CO6440577A2 - Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona - Google Patents

Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona

Info

Publication number
CO6440577A2
CO6440577A2 CO11132796A CO11132796A CO6440577A2 CO 6440577 A2 CO6440577 A2 CO 6440577A2 CO 11132796 A CO11132796 A CO 11132796A CO 11132796 A CO11132796 A CO 11132796A CO 6440577 A2 CO6440577 A2 CO 6440577A2
Authority
CO
Colombia
Prior art keywords
derivatives
quinazolinadiona
therapeutic applications
phosphodiesterase
compounds
Prior art date
Application number
CO11132796A
Other languages
English (en)
Inventor
Philip Janiak
Gilbert Marciniak
Jean-Francois Nave
Fabrice Viviani
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO6440577A2 publication Critical patent/CO6440577A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos que comprenden derivados de quinazolinadiona, susceptibles de actuar como inhibidores de la fosfodiesterasa 7 (PDE7) e incluso de la fosfodiesterasa 8 (PDE8) y útiles para la preparación de medicamentos para tratar enfermedades cardiovasculares. Estos compuestos pueden existir en forma de isómeros de tipo rotámero o atropoisómero, en forma de bases o de sales de adición a ácidos, en forma cristalina, amorfa u oleosa y en forma de hidratos o de solvatos.
CO11132796A 2009-04-09 2011-10-07 Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona CO6440577A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0901755A FR2944206B1 (fr) 2009-04-09 2009-04-09 Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione

Publications (1)

Publication Number Publication Date
CO6440577A2 true CO6440577A2 (es) 2012-05-15

Family

ID=41181038

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11132796A CO6440577A2 (es) 2009-04-09 2011-10-07 Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona

Country Status (35)

Country Link
US (1) US8846654B2 (es)
EP (1) EP2416777B1 (es)
JP (1) JP5685578B2 (es)
KR (1) KR101686267B1 (es)
CN (1) CN102458409B (es)
AR (1) AR076232A1 (es)
AU (1) AU2010233596B2 (es)
BR (1) BRPI1010256A2 (es)
CA (1) CA2758234A1 (es)
CL (1) CL2011002525A1 (es)
CO (1) CO6440577A2 (es)
CR (1) CR20110527A (es)
CY (1) CY1115987T1 (es)
DK (1) DK2416777T3 (es)
DO (1) DOP2011000306A (es)
EA (1) EA020984B1 (es)
EC (1) ECSP11011377A (es)
ES (1) ES2528633T3 (es)
FR (1) FR2944206B1 (es)
HK (1) HK1165997A1 (es)
HR (1) HRP20150106T1 (es)
HU (1) HUE024161T2 (es)
IL (1) IL215610A (es)
MA (1) MA33254B1 (es)
MX (1) MX2011010645A (es)
NI (1) NI201100180A (es)
NZ (1) NZ595660A (es)
PL (1) PL2416777T3 (es)
PT (1) PT2416777E (es)
SG (2) SG175131A1 (es)
SI (1) SI2416777T1 (es)
TN (1) TN2011000506A1 (es)
TW (1) TWI457330B (es)
UY (1) UY32555A (es)
WO (1) WO2010116090A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
US9499496B2 (en) 2012-06-05 2016-11-22 University Of Kansas Inhibitors of respiratory syncytial virus
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879393A (en) * 1973-06-18 1975-04-22 Miles Lab Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones
JPS56164172A (en) * 1980-05-22 1981-12-17 Masayuki Ishikawa Novel 2,4 1h,3h -quinazolinedione derivative
EP0040793B1 (en) * 1980-05-22 1985-08-28 Masayuki Ishikawa Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
US5624926A (en) 1993-02-18 1997-04-29 Kyowa Hakko Kogyo Co., Ltd. Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors
US6384080B1 (en) 1998-04-20 2002-05-07 Fujisawa Pharmaceutical Co., Ltd. Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase
AU2525701A (en) 1999-12-14 2001-06-25 Sanofi-Synthelabo Derivatives of quinazolinedione phthalimide, preparations thereof and their therapeutic uses
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
CA2599662A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
US7846664B2 (en) 2005-12-07 2010-12-07 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
CN104758291B (zh) 2007-03-27 2020-03-03 奥默罗斯公司 用于治疗运动障碍的pde7抑制剂的用途
EP2138482A4 (en) 2007-04-19 2011-06-15 Astellas Pharma Inc BICYCLIC HETEROCYCLIC COMPOUND
FR2921926B1 (fr) * 2007-10-03 2009-12-04 Sanofi Aventis Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione

Also Published As

Publication number Publication date
FR2944206A1 (fr) 2010-10-15
CA2758234A1 (fr) 2010-10-14
CY1115987T1 (el) 2017-01-25
PL2416777T3 (pl) 2015-05-29
EA201171229A1 (ru) 2012-12-28
EP2416777A1 (fr) 2012-02-15
NI201100180A (es) 2012-01-11
SI2416777T1 (sl) 2015-02-27
US8846654B2 (en) 2014-09-30
JP2012523398A (ja) 2012-10-04
DOP2011000306A (es) 2011-10-31
JP5685578B2 (ja) 2015-03-18
CL2011002525A1 (es) 2012-02-17
FR2944206B1 (fr) 2012-12-28
AU2010233596B2 (en) 2016-06-23
AR076232A1 (es) 2011-05-26
DK2416777T3 (en) 2015-02-09
KR20120005499A (ko) 2012-01-16
AU2010233596A1 (en) 2011-11-03
HUE024161T2 (hu) 2016-02-29
TWI457330B (zh) 2014-10-21
MA33254B1 (fr) 2012-05-02
BRPI1010256A2 (pt) 2016-03-22
TN2011000506A1 (fr) 2013-05-24
CN102458409A (zh) 2012-05-16
TW201040155A (en) 2010-11-16
IL215610A0 (en) 2011-12-29
SG175131A1 (en) 2011-11-28
CN102458409B (zh) 2014-06-18
PT2416777E (pt) 2015-02-04
ES2528633T3 (es) 2015-02-11
EA020984B1 (ru) 2015-03-31
IL215610A (en) 2013-07-31
UY32555A (es) 2010-11-30
WO2010116090A1 (fr) 2010-10-14
HK1165997A1 (en) 2012-10-19
NZ595660A (en) 2013-03-28
SG10201400420PA (en) 2014-05-29
EP2416777B1 (fr) 2014-11-12
HRP20150106T1 (hr) 2015-05-08
CR20110527A (es) 2014-05-12
ECSP11011377A (es) 2011-11-30
US20120184522A1 (en) 2012-07-19
MX2011010645A (es) 2012-01-19
KR101686267B1 (ko) 2016-12-13

Similar Documents

Publication Publication Date Title
CR11793A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
PE20150998A1 (es) Inhibidores de histona demetilasas
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
GT200900027A (es) Compuestos organicos
SV2010003777A (es) Compuestos organicos
CU20110145A7 (es) Derivados de sulfonamida
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
DOP2011000102A (es) Compuestos heteroaromaticos espirociclicos fusionados para el tratamiento de infecciones bacterianas
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
PA8821301A1 (es) Inhibidores a base de hidroxamato de desacetilasas b
CO6382114A2 (es) Inhibidores de cinasa akt y p70 s6
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
CO6741154A2 (es) Compuestos de triazolopiridina
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
HN2011001019A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk) produccion y uso de los mismos como productos medicinales
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
AR085308A1 (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea

Legal Events

Date Code Title Description
FC Application refused